The purpose of this study is to determine the clinical benefits of using a rapidly cycling,
non-cross reactive regimen of FDA-approved prostate cancer therapeutic agents in the
management of castration resistant prostate cancer. The hypothesis is that the identification
of optimal combinations and sequencing of therapies can help prevent or delay the development
of therapeutic drug resistance, and can be safely tolerated.